Page last updated: 2024-12-06

panipenem

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Panipenem is a carbapenem antibiotic that was initially developed as a broad-spectrum agent for the treatment of various bacterial infections. It is a synthetic analog of the naturally occurring antibiotic thienamycin, modified to enhance its stability and resistance to breakdown by bacterial enzymes. Panipenem exhibits potent activity against a wide range of Gram-positive and Gram-negative bacteria, including multi-drug resistant strains. Despite its promising initial development, it has not been widely used due to its complex synthesis process and potential for adverse effects, such as seizures. However, ongoing research focuses on investigating panipenem's potential as a salvage therapy for infections resistant to other antibiotics and evaluating its effectiveness in combination therapies.'

panipenem: synthetic cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72015
CHEMBL ID339323
CHEBI ID7911
SCHEMBL ID150517
MeSH IDM0118328

Synonyms (42)

Synonym
87726-17-8
penipanem
(5r,6s)-3-[(3s)-1-ethanimidoylpyrrolidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
panipenem
(5r,6s)-2-[1-acetamidoylpyrrolidin-3(s)-ylthio]-6-[1(r)-hydroxyethyl]-2-carbapenem-3-carboxylic acid
rs-533
cs-533
6-(1-hydroxyethyl)-2-(1-acetimidoylpyrrolidin-3-ylthio)-1-carbaren-2-em-3-carboxylic acid
rs 533
panipenem [inn:jan]
panipenemum [inn-latin]
carbapenem rs-533
cs 533
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((1-(1-iminoethyl)-3-pyrrolidinyl)thio)-7-oxo-, (5r-(3(s*),5-alpha,6-alpha(r*)))-
(+)-(5r,6s)-3-(((s)-1-acetimidoyl-3-pyrrolidinyl)thio)-6-((r)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
papm
D01048
panipenem (jp17/inn)
CHEMBL339323
panipenemum
unii-w9769w09jf
w9769w09jf ,
AKOS015895977
SCHEMBL150517
panipenem [who-dd]
panipenem [inn]
98167-70-5
panipenem [mi]
panipenem [mart.]
panipenem [jan]
AC-22713
CHEBI:7911
TYMABNNERDVXID-DLYFRVTGSA-N
DTXSID20868982
Q7131192
A13096
(5r,6s)-6-((r)-1-hydroxyethyl)-3-(((s)-1-(1-iminoethyl)pyrrolidin-3-yl)thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(5r,6s)-6-((r)-1-hydroxyethyl)-3-(((s)-1-(1-iminoethyl)pyrrolidin-3-yl)thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid
CS-0034692
HY-111227
carbenin (panipenem + betamipron)
gtpl12184

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with panipenem had no effect on the plasma concentration-time curves and biliary excretion of SN-38 and SN-38G in rats with and without bile duct cannulation."( Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
Abe, F; Hasegawa, T; Hotta, K; Kato, A; Kondo, F; Oshima, T; Saito, H; Tsukiyama, I; Ueyama, J, 2011
)
2.14

Toxicity

ExcerptReferenceRelevance
" This life-threatening complication, equivalent to a grade 4 non-hematological adverse reaction, was not counted as dose-limiting toxicity in the current phase I trial, because there are only a few reports of bacterial meningitis associated with cancer chemotherapy and it developed in this case without any associated decrease in the peripheral blood leukocyte count."( Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity.
Kodama, T; Kunitoh, H; Matsuda, T; Ohe, Y; Saijo, N; Saisho, T; Sekine, I; Tamura, T; Watanabe, H; Yamamoto, N, 2000
)
0.31

Pharmacokinetics

The pharmacokinetic behavior of panipenem in patients with ESRD was compared to that of a surrogate marker of efficacy. We recommend that these patients be treated with 500 mg/500 mg of panineem/betamipron once daily, which gives a similar clinical result in a patient with normal renal function.

ExcerptReferenceRelevance
" There were good allometric correlations between pharmacokinetic parameters (CLtotal and Vd,ss) calculated from the plasma concentration in animal species and body weight of experimental animals."( Prediction of human pharmacokinetics of panipenem, a new carbapenem antibiotic, from animal data.
Hisaoka, M; Kurihara, A; Nakashima, M, 1992
)
0.55
" All the data for the 108 serum panipenem concentrations were evaluated with a non-linear mixed-effect model (NONMEM with first-order method), a computer program designed for population pharmacokinetic analysis."( Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage.
Kimura, T; Kokubun, H; Kubo, H; Matsuura, N; Nowatari, M; Sunakawa, K, 2001
)
0.88
" Population pharmacokinetic studies were performed to determine the optimal dosage regimens for three types of antibiotics: an aminoglycoside, arbekacin; a glycopeptide, vancomycin; and a carbapenem, panipenem."( Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
Kimura, T; Kubo, H; Matsuura, N; Shimada, S; Sunakawa, K; Yago, K, 2004
)
0.76
" After comparing the pharmacokinetic behavior of panipenem in patients with ESRD and that of a surrogate marker of efficacy, we recommend that these patients be treated with 500 mg/500 mg of panipenem/betamipron once daily, which gives a similar clinical result in a patient with normal renal function."( Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease.
Hishida, A; Kanamaru, M; Nagashima, S; Ohashi, N; Tajima, N; Togawa, A; Uematsu, T, 2005
)
0.91
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
"Carbapenem antibiotics cause pharmacokinetic interaction with valproic acid (VPA) in clinical pharmacotherapy."( Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human.
Kiribayashi, Y; Maeda, Y; Murakami, T; Nagai, J; Omoda, K; Takano, M; Yumoto, R, 2005
)
0.33
"The pharmacokinetics of panipenem in experimental renal failure animal models was investigated in order to identify the appropriate covariates affecting the pharmacokinetic behavior."( Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats.
Ishizuka, H; Naganuma, H; Soma, M; Tajima, N, 2005
)
0.86
"Population pharmacokinetic analyses were performed with plasma concentrations from 26 healthy volunteers and 41 patients."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.6
" Pharmacokinetic values of PAPM were measured in 4 patients with CRRT."( Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.
Fujita, I; Gando, S; Hayakawa, M; Iseki, K; Ito, Y,
)
0.38
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

The dosage regimen of panipenem for patients with renal impairment should be reduced when creatinine clearance is lower than 60 ml/min. Because 30% of panIPenem and most of the betamipron are excreted in the urine in an unchanged form, renal function is the important determinant.

ExcerptRelevanceReference
" Our findings suggest that the panipenem dosage regimen of 10-20 mg/kg every 12 h should yield concentrations within the accepted therapeutic range."( Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage.
Kimura, T; Kokubun, H; Kubo, H; Matsuura, N; Nowatari, M; Sunakawa, K, 2001
)
0.88
"Immature renal function in neonates requires antibiotic dosage adjustment."( Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
Kimura, T; Kubo, H; Matsuura, N; Shimada, S; Sunakawa, K; Yago, K, 2004
)
0.57
" Because 30% of panipenem and most of the betamipron are excreted in the urine in an unchanged form, renal function is the important determinant of the dosage regimen of panipenem/betamipron."( Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease.
Hishida, A; Kanamaru, M; Nagashima, S; Ohashi, N; Tajima, N; Togawa, A; Uematsu, T, 2005
)
1
"Although plasma concentrations of panipenem were elevated and the risk of adverse events would increase in patients with renal impairment, a precise dosage regimen for patients with renal impairment has not been established."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.88
" Optimal dosage regimens for patients with renal impairment were determined based on the bacteriostatic index of C(20%T)>(MIC), the concentration corresponding to the time above MIC of 20% of the dosing interval."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.6
"The dosage regimen of panipenem for patients with renal impairment should be reduced when creatinine clearance is lower than 60 ml/min."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.92
" These results suggest that our simple and rapid HPLC method for the determination of the serum concentrations of carbapenems is useful for pharmacokinetic/pharmacodynamic (PK/PD)-based determination of carbapenem dosage regimens."( Simple and rapid determination of serum carbapenem concentrations by high-performance liquid chromatography.
Hori, S; Kizu, J; Kurihara, Y, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (127)

Assay IDTitleYearJournalArticle
AID534691Antimicrobial activity against Prevotella intermedia by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534427Antimicrobial activity against Anaerococcus prevotii ATCC 9321 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534671Antimicrobial activity against Prevotella oris ATCC 33573 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534456Antimicrobial activity against Lactobacillus fermentum JCM 1173 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID534675Antimicrobial activity against Fusobacterium varium ATCC 8501 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534434Antimicrobial activity against Gemella morbillorum ATCC 27824 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID56142Tested for stability of compound to swine renal DHP-1 relative to imipenem (IMP); Not tested2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID534429Antimicrobial activity against Finegoldia magna ATCC 29328 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534667Antimicrobial activity against Prevotella intermedia ATCC 25611 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID534475Antimicrobial activity against Campylobacter gracilis JCM 8538 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534709Antimicrobial activity against Clostridium difficile by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534446Antimicrobial activity against Bifidobacterium bifidum JCM 1255 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534705Antimicrobial activity against Peptostreptococcus anaerobius by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534697Antimicrobial activity against Fusobacterium nucleatum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534706Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534477Antimicrobial activity against Prevotella bivia ATCC 29303 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534698Antimicrobial activity against Fusobacterium necrophorum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534704Antimicrobial activity against Parvimonas micra by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534683Antimicrobial activity against Bacteroides fragilis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID534694Antimicrobial activity against Porphyromonas asaccharolyticus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534701Antimicrobial activity against Fusobacterium sp. by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID534680Antimicrobial activity against Capnocytophaga ochracea GAI 5586 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534469Antimicrobial activity against Parabacteroides distasonis ATCC 8503 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534432Antimicrobial activity against Peptoniphilus indolicus GAI 0915 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534699Antimicrobial activity against Fusobacterium varium by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534692Antimicrobial activity against Prevotella sp. by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534700Antimicrobial activity against Fusobacterium mortiferum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534465Antimicrobial activity against Bacteroides fragilis GAI 10150 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534478Antimicrobial activity against Prevotella buccae ATCC 33574 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534687Antimicrobial activity against Bacteroides vulgatus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534702Antimicrobial activity against Desulfovibrio desulfuricans by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534471Antimicrobial activity against Bacteroides thetaiotaomicron ATCC 29741 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534457Antimicrobial activity against Lactobacillus plantarum JCM 1149 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534436Antimicrobial activity against Streptococcus constellatus ATCC 27923 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID534461Antimicrobial activity against Bacteroides fragilis ATCC 25285 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534708Antimicrobial activity against Eubacterium limosum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534463Antimicrobial activity against Bacteroides fragilis GAI 0558 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID559859Antimicrobial activity against Streptococcus agalactiae clinical isolates by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.
AID534473Antimicrobial activity against Bacteroides eggerthii ATCC 27754 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534464Antimicrobial activity against Bacteroides fragilis GAI 7955 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534688Antimicrobial activity against Bacteroides caccae by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534686Antimicrobial activity against Bacteroides uniformis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534442Antimicrobial activity against Clostridium sordellii ATCC 9714 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534450Antimicrobial activity against Eggerthella lenta ATCC 25559 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534710Antimicrobial activity against Clostridium perfringens by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID206268In vitro antibacterial activity against Staphylococcus aureus 3004 Methicillin-resistant Staphylococcus aureus.2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID534689Antimicrobial activity against Bacteroides stercoris by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534438Antimicrobial activity against Clostridium clostridioforme NCTC 11224 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1449630Half life in iv dosed human2017European journal of medicinal chemistry, May-05, Volume: 131Recent updates of carbapenem antibiotics.
AID534695Antimicrobial activity against Porphyromonas gingivalis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1449638Drug uptake in end-stage renal disease patient blood at 0.5 g, iv2017European journal of medicinal chemistry, May-05, Volume: 131Recent updates of carbapenem antibiotics.
AID534458Antimicrobial activity against Lactobacillus reuteri JCM 1112 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534443Antimicrobial activity against Clostridium ramosum ATCC 25582 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID7633Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID534696Antimicrobial activity against Porphyromonas uenonis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534455Antimicrobial activity against Lactobacillus casei subsp. casei JCM 1134 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534670Antimicrobial activity against Prevotella oralis ATCC 33269 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534678Antimicrobial activity against Desulfovibrio desulfuricans ATCC 29577 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID56133Tested for stability of compound to human renal DHP-1 relative to imipenem (IMP); Not tested2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID534460Antimicrobial activity against Bacteroides fragilis GAI 5562 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534466Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30079 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534679Antimicrobial activity against Desulfovibrio piger DSM 749 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534684Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534690Antimicrobial activity against Odoribacter splanchnicus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534685Antimicrobial activity against Parabacteroides distasonis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534459Antimicrobial activity against Lactobacillus salivarius subsp. salivarius JCM 1231 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534707Antimicrobial activity against Eggerthella lenta by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1449636Clearance in end-stage renal disease patient undergoing drug hydrolysis2017European journal of medicinal chemistry, May-05, Volume: 131Recent updates of carbapenem antibiotics.
AID534673Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534447Antimicrobial activity against Bifidobacterium breve ATCC 15700 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534703Antimicrobial activity against Finegoldia magna by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534693Antimicrobial activity against Prevotella melaninogenica by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534448Antimicrobial activity against Bifidobacterium longum subsp. longum ATCC 15707 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID534433Antimicrobial activity against Peptostreptococcus anaerobius ATCC 27337 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534479Antimicrobial activity against Prevotella corporis GAI 91000 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534668Antimicrobial activity against Prevotella melaninogenica JCM 6325 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534451Antimicrobial activity against Propionibacterium acnes ATCC 11828 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID206267In vitro antibacterial activity against Staphylococcus aureus 209P JC-1.2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID534441Antimicrobial activity against Clostridium septicum ATCC 12464 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534462Antimicrobial activity against Bacteroides fragilis NCTC 10581 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534672Antimicrobial activity against Porphyromonas asaccharolyticus ATCC 25260 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534474Antimicrobial activity against Bacteroides ureolyticus NCTC 10941 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534444Antimicrobial activity against Actinomyces odontolyticus GAI 91002 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534470Antimicrobial activity against Bacteroides ovatus ATCC 8483 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID534430Antimicrobial activity against Parvimonas micra VPI 5464-1 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534431Antimicrobial activity against Peptoniphilus asaccharolyticus WAL 3218 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534454Antimicrobial activity against Lactobacillus brevis subsp. brevis JCM 1059 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534467Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30144 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534452Antimicrobial activity against Propionibacterium granulosum ATCC 25564 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534676Antimicrobial activity against Fusobacterium necrophorum ATCC 25286 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1449639Drug uptake in end-stage renal disease patient blood at 0.75 g, iv2017European journal of medicinal chemistry, May-05, Volume: 131Recent updates of carbapenem antibiotics.
AID534439Antimicrobial activity against Clostridium difficile GAI 10029 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534472Antimicrobial activity against Bacteroides uniformis ATCC 8492 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534437Antimicrobial activity against Streptococcus intermedius ATCC 27335 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534449Antimicrobial activity against Bifidobacterium pseudolongum ATCC 25526 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534440Antimicrobial activity against Clostridium perfringens ATCC 13124 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534480Antimicrobial activity against Prevotella heparinolytica ATCC 35895 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534669Antimicrobial activity against Prevotella denticola GAI 5490 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID71048In vitro antibacterial activity against Escherichia coli NIHJ JC-2.2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID534677Antimicrobial activity against Bilophila wadsworthia WAL 7959 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID534445Antimicrobial activity against Bifidobacterium adolescentis ATCC 15703 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534681Antimicrobial activity against Veillonella parvula ATCC 10790 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID164578In vitro antibacterial activity against Ps. auruginosa 26.2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID1449637Clearance in end-stage renal disease patient without drug hydrolysis2017European journal of medicinal chemistry, May-05, Volume: 131Recent updates of carbapenem antibiotics.
AID534453Antimicrobial activity against Lactobacillus acidophilus JCM 1132 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534674Antimicrobial activity against Fusobacterium nucleatum ATCC 25586 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534435Antimicrobial activity against Staphylococcus saccharolyticus ATCC 14953 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534682Antimicrobial activity against Veillonella dispar ATCC 17748 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID163079In vitro antibacterial activity against Proteus vulgaris IAM 1025.2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID534468Antimicrobial activity against Bacteroides vulgatus GAI 0673 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534428Antimicrobial activity against Atopobium parvulum VPI 0546 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID1449640Ratio of drug level in serum to cerebrospinal fluid in human2017European journal of medicinal chemistry, May-05, Volume: 131Recent updates of carbapenem antibiotics.
AID534476Antimicrobial activity against Sutterella wadsworthensis ATCC 51579 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (92)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (4.35)18.7374
1990's33 (35.87)18.2507
2000's45 (48.91)29.6817
2010's9 (9.78)24.3611
2020's1 (1.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.26 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index38.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (5.21%)5.53%
Reviews5 (5.21%)6.00%
Case Studies13 (13.54%)4.05%
Observational0 (0.00%)0.25%
Other73 (76.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]